Establishment and genetic characterization of ANGM-CSS, a novel, immortal cell line derived from a human glioblastoma multiforme

International Journal of Oncology

Volumn 44, Issue 3, 2014, Pages 717-724

  Notarangelo, Angelantonio ^a   Trombetta, Domenico ^a   D'Angelo, Vincenzo ^a   Parrella, Paola ^a   Palumbo, Orazio ^a   Tiziana Storlazzi, Clelia ^b   Impera, Luciana ^b   Muscarella, Lucia Anna ^a   La Torre, Antonella ^a   Affuso, Andrea ^c   Fazio, Vito Michele ^a   Carella, Massimo ^a   Zelante, Leopoldo ^a  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c Grande Ospedale Metropolitano   (Italy)

Author keywords

Cytogenetics; Fluorescent in situ hybridization; Glioblastoma cell line; In vitro test system

Indexed keywords

CD133 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; GLIAL FIBRILLARY ACIDIC PROTEIN; MESSENGER RNA; NESTIN; SCATTER FACTOR RECEPTOR; TEMOZOLOMIDE; VIMENTIN;

ADULT; ANGM CSS CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CASE REPORT; CELL IMMORTALIZATION; CHROMOSOME ANALYSIS; CHROMOSOME NUMBER; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; CYTOGENETICS; GENE OVEREXPRESSION; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; KARYOTYPE; MALE; MIDDLE AGED; MORPHOLOGY; MOUSE; MULTIMODALITY CANCER THERAPY; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; TETRAPLOIDY; TISSUE CHARACTERIZATION; XENOGRAFT;

ANIMALS; BRAIN NEOPLASMS; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; GLIOBLASTOMA; HUMANS; KARYOTYPING; MICE;

EID: 84896728227     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2224     Document Type: Article

References (39)

1. Furnari FB, Fenton T, Bachoo RM, et al: Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 21: 2683-26710, 2007.
2. Porter K, McCarthy B, Berbaum M, et al: Conditional survival of all primary brain tumor patients by age, behavior, and histology. Neuroepidemiology 36: 230-239, 2011.
3. Preusser M, de Ribaupierre S, Wöhrer A, et al: Current concepts and management of glioblastoma. Ann Neurol 70: 9-21, 2011.
4. Cheng L, Wu Q, Guryanova O, et al: Elevated invasive potential of glioblastoma stem cells. Biochem Biophys Res Commun 406: 643-648, 2011.
5. Louis DN, Ohgaki H, Wiestler OD, et al: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114: 97-109, 2007.
6. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005.
7. Stupp R, Hegi ME, Mason WP, et al: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10: 459-466, 2009.
8. Wen PY and Kesari S: Malignant gliomas in adults. N Engl J Med 359: 492-507, 2008.
9. Bakir A, Gezen F, Yildiz O, et al: Establishment and characterization of a human glioblastoma multiforme cell line. Cancer Genet Cytogenet 103: 46-51, 1998.
10. Nuki Y, Uchinokura S, Miyata S, et al: Establishment and characterization of a new human glioblastoma cell line, NYGM. Hum Cell 17: 145-150, 2004.
11. Wang J, Wang X, Jiang S, et al: Establishment of a new human glioblastoma multiforme cell line (WJ1) and its partial characterization. Cell Mol Neurobiol 27: 831-843, 2007.
12. Fomchenko EI and Holland EC: Mouse models of brain tumors and their applications in preclinical trials. Clin Cancer Res 12: 5288-5297, 2006.
13. Palumbo O, Palumbo P, Palladino T, et al: A novel deletion in 2q24.1q24.2 in a girl with mental retardation and generalized hypotonia: a case report. Mol Cytogenet 5: 1, 2012.
14. Macchia G, Trombetta D, Möller E, et al: FOSL1 as a candidate target gene for 11q12 rearrangements in desmoplastic fibroblastoma. Lab Invest 92: 735-743, 2012.
15. Scintu M, Vitale R, Prencipe M, et al: Genomic instability and increased expression of BUB1B and MAD2L1 genes in ductal breast carcinoma. Cancer Lett 254: 298-307, 2012.
16. Parrella P, la Torre A, Copetti M, et al: High specificity of quantitative methylation-specific PCR analysis for MGMT promoter hypermethylation detection in gliomas. J Biomed Biotechnol 2009: 531692, 2009.
17. Hibi K, Robinson CR, Booker S, et al: Molecular detection of genetic alterations in the serum of colorectal cancer patients. Cancer Res 58: 1405-1407, 1998.
18. Gu TL, Deng X, Huang F, et al: Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma. PLoS One 6: e15640, 2011.
19. Singh D, Chan JM, Zoppoli P, et al: Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 337: 1231-1235, 2012.
20. Charest A, Lane K, McMahon K, et al: Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21). Genes Chromosomes Cancer 37: 58-71, 2003.
21. Burfeind P, Chernicky CL, Rininsland F, et al: Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo. Proc Natl Acad Sci USA 93: 7263-7268, 1996.
22. Shaffer LG, Slovak ML and Campbell LJ (eds): ISCN 2009: An International System for Human Cytogenetic Nomenclature. S. Karger, Basel, 2009.
23. Lolait SJ, Harmer JH, Auteri G, et al: Expression of glial fibrillary acidic protein, actin, fibronectin and factor VIII antigen in human astrocytomas. Pathology 15: 373-378, 1983.
24. Lipsky RH and Silverman SJ: Effects of mycophenolic acid on detection of glial filaments in human and rat astrocytoma cultures. Cancer Res 47: 4900-4904, 1987.
25. Bocchini V, Casalone R, Collini P, et al: Changes in glial fibrillary acidic protein and karyotype during culturing of two cell lines established from human glioblastoma multiforme. Cell Tissue Res 265: 73-81, 1991.
26. Veselska R, Kuglik P, Cejpek P, et al: Nestin expression in the cell lines derived from glioblastoma multiforme. BMC Cancer 6: 32, 2003.
27. Jiang Y and Uhrbom L: On the origin of glioma. Ups J Med Sci 117: 113-121, 2012.
28. Krupkova O, Loja T, Zambo I, et al: Nestin expression in human tumors and tumor cell lines. Neoplasma 57: 291-298, 2010.
29. Bigner DD, Bigner SH, Ponten J, et al: Heterogeneity of Genotypic and phenotypic characteristics of fifteen permanent cell lines derived from human gliomas. J Neuropathol Exp Neurol 40: 201-229, 1981.
30. Roversi G, Pfundt R, Moroni RF, et al: Identification of novel genomic markers related to progression to glioblastoma through genomic profiling of 25 primary glioma cell lines. Oncogene 25: 1571-1583, 2006.
31. Dahlback HS, Brandal P, Meling TR, et al: Genomic aberrations in 80 cases of primary glioblastoma multiforme: Pathogenetic heterogeneity and putative cytogenetic pathways. Genes Chromosomes Cancer 48: 908-924, 2009.
32. Rey JA, Bello MJ, de Campos JM, et al: Chromosomal patterns in human malignant astrocytomas. Cancer Genet Cytogenet 29: 201-221, 1987.
33. Bigner SH, Mark J and Bigner DD: Cytogenetics of human brain tumors. Cancer Genet Cytogenet 47: 141-154, 1990.
34. Kruse CA, Mitchell DH, Kleinschmidt-DeMasters BK, et al: Characterization of a continuous human glioma cell line DBTRG-05MG: growth kinetics, karyotype, receptor expression, and tumor suppressor gene analyses. In Vitro Cell Dev Biol 28A: 609-614, 1992.
35. Gjerset RA, Fakhrai H, Shawler DL, et al: Characterization of a new human glioblastoma cell line that expresses mutant p53 and lacks activation of the PDGF pathway. In Vitro Cell Dev Biol Anim 31: 207-214, 1995.
36. Cancer Genome Atlas Research Network: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068, 2008.
37. Uhrinova S, Uhrin D, Powers H, et al: Structure of free MDM2 N-terminal domain reveals conformational adjustments that accompany p53-binding. J Mol Biol 350: 587-598, 2005.
38. Esteller M, Garcia-Foncillas J, Andion E, et al: Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343: 1350-1354, 2000.
39. Hegi ME, Diserens AC, Gorlia T, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352: 997-1003, 2005.